依那西普治疗银屑病的疗效和安全性

Efficacy and safety of etanercept in the management of psoriasis

依那西普为肿瘤坏死因子α的拮抗剂，可用于治疗斑块状银屑病和银屑病关节炎。近期完成的Ⅱ、Ⅲ期临床试验证明，短期25mg或50mg皮下注射，每周2次连续12周，或者更长期的依那西普治疗．可以明显改善患者的症状和生活质量，不良反应较少且轻微，与对照组之间差异无统计学意义，在治疗儿童重度银屑病方面也有很好前景。依那西普可作为中重度斑块状银屑病和银屑病关节炎患者的治疗选择，但仍需进一步的大规模临床试验以充分明确其各方面特性。

Etanercept, a tumor necrosis factor-α （ TNF-α ） antagonist, is used for the treatment of plaque psoriasis and psoriatic arthritis. As phase Ⅱ and Ⅲ clinical trials have proved, short term （ 25mg or 50mg subcutaneously twice a week for 12 weeks ）or longer etanercept therapy can significantly improve patients＇ symptoms and quality of life, with few mild adverse events. Also, it has good prospect in the treatment of severe pediatric psoriasis. It has been proven to be a good option for the treatment of moderate to severe plaque psoriasis and psoriatic arthritis; however, large-scale clinical trials are needed to thoroughly recognize its characteristics.